In this article, we will list the 5 Under-the-Radar Stocks with Massive Upside for 2026. Please visit 10 Under-the-Radar Stocks with Massive Upside for 2026 if you’d like to see an extended list and the methodology behind it.

5. MakeMyTrip Limited (NASDAQ:MMYT)

MakeMyTrip Limited (NASDAQ:MMYT), with 74.3% upside potential, ranks among the under-the-radar stocks with massive upside for 2026.

Two analysts lowered their price targets on MakeMyTrip Limited (NASDAQ:MMYT) after Q4 fiscal 2026 results, citing geopolitical headwinds and estimate resets, even as both kept bullish ratings on the stock.

On May 20, 2026, Citi analyst Vijit Jain cut the firm’s price target on MakeMyTrip Limited (NASDAQ:MMYT) to $70 from $80 while keeping a “Buy” rating. Jain noted that the adjusted EBIT of $46 million came in 2% ahead of his estimates, with constant currency growth in gross bookings and adjusted revenues at 5% and 13% year-over-year, respectively. The firm said it is lowering estimates to factor in the prolonged impact of the geopolitical situation, and now builds in 3% and 6% year-over-year growth in gross booking value for Q1 and full-year fiscal 2027, respectively.

Those results came from MakeMyTrip Limited (NASDAQ:MMYT)’s Q4 fiscal 2026 earnings call on May 19, 2026. Management said the quarter was impacted by the West Asia conflict, which weighed on westbound international travel and pushed up domestic airfares. Despite that, the company reported full-year fiscal 2026 gross bookings of $10.4 billion and IFRS revenue growth of 10.7% in constant currency. Full-year adjusted operating profit margin expanded to 1.82% of gross bookings from 1.71% in fiscal 2025. The company ended the quarter with cash and equivalents of over $782 million. Management said it remains cautiously optimistic and flagged continued near-term uncertainty from the conflict.

Ahead of the results, Goldman Sachs analyst Manish Adukia cut the firm’s price target to $80 from $117 on May 8, 2026, while keeping a “Buy” rating on MakeMyTrip Limited (NASDAQ:MMYT). Adukia cited steady estimate downgrades through fiscal 2026, demand headwinds, INR depreciation, AI disruption concerns, a potential India listing, and convertible bond redemption worries as factors weighing on the stock’s multiple.

Founded in 2000 and headquartered in Gurgaon, India, MakeMyTrip Limited (NASDAQ:MMYT) operates a leading online travel platform offering airline tickets, hotel reservations, holiday packages, and rail and bus bookings. Its scale, expanding inventory, and strong brand recognition position it to benefit from sustained growth in India’s travel and tourism sector.

4. BETA Technologies, Inc. (NYSE:BETA)

With an analyst consensus upside of 90.9%, BETA Technologies, Inc. (NYSE:BETA) ranks among the under-the-radar stocks with massive upside for 2026.

Two analysts trimmed their price targets on Beta Technologies (BETA) while holding onto their bullish ratings, even as the stock sits 40% lower year-to-date.

On May 20, 2026, BTIG cut its price target on BETA Technologies, Inc. (NYSE:BETA) to $33 from $40, keeping a “Buy” rating.

The firm cited revised delivery expectations as the driver of the reduction. BTIG noted BETA Technologies, Inc. (NYSE:BETA) holds a dominant position on the eVTOL Integration Pilot Program initiative, with awards across seven of the eight projects, representing the most of any original equipment manufacturer. The firm said executing on those awards will pull forward labor and materials spend, but added that the incremental investment meaningfully de-risks the path to commercialization and could accelerate commercial readiness by approximately one year. BTIG said the developments further reinforce Beta Technologies’ leadership in Advanced Air Mobility.

On May 18, 2026, Citi analyst John Godyn lowered the firm’s price target on BETA Technologies, Inc. (NYSE:BETA) to $25 from $33, also keeping a “Buy” rating.

Godyn said the firm updated models across the aerospace and defense sector and does not expect an “immediate V-shaped rally” without a resolution to the Middle East conflict. Citi still sees buying opportunities following recent selloffs, expecting the aerospace group to rally first, followed by defense.

BETA Technologies, Inc. (NYSE:BETA) develops and manufactures electric aircraft platforms and propulsion systems in the United States, including electric aircraft, advanced propulsion systems, charging infrastructure, and related components for the aviation industry.

3. Ondas Inc. (NASDAQ:ONDS)

With an analyst consensus upside of 115.2%, Ondas Inc. (NASDAQ:ONDS) ranks among the under-the-radar stocks with massive upside for 2026.

Ondas Inc. (NASDAQ:ONDS) drew fresh analyst support after announcing its acquisition of Omnisys, an Israeli AI-powered defense software developer.

On May 19, 2026, Needham reiterated a “Buy” rating and $23.00 price target on Ondas Inc. (NASDAQ:ONDS), calling the deal one of Ondas’ most strategically significant transactions to date. The firm said the acquisition adds a software orchestration layer that transforms Ondas’ portfolio into a fully integrated multi-domain autonomous warfare platform. Needham estimates Omnisys could generate $30 million to $40 million in pro forma 2026 revenue, with greater upside in 2027 as Ondas scales adoption across allied markets.

The analyst note followed Ondas Inc. (NASDAQ:ONDS)’s announcement on May 18, 2026, that it had entered into a definitive agreement to acquire 100% of Omnisys Ltd.

The deal closed on May 21, 2026, with Ondas Inc. (NASDAQ:ONDS) paying approximately $196.6 million in common stock, structured through shares issued at closing, escrowed stock, and additional stock consideration paid in staged installments. Sellers are subject to daily trading volume limits on share sales, and Ondas has granted registration rights to enable future resale under U.S. securities rules.

Omnisys develops the Battle Resource Optimization (BRO) platform, a vendor-agnostic AI software suite with more than 25 years of operational deployment in advanced defense environments, including complex multi-layer air defense operations. The BRO platform integrates data across sensors, command-and-control systems, and autonomous assets to support real-time mission planning, resource optimization, and battlefield decision-making.

CEO Eric Brock said BRO is a “proven, battle-tested software platform” that will strengthen Ondas Inc. (NASDAQ:ONDS)’s ability to integrate into existing customer infrastructures and deliver scalable solutions for global defense markets.

Ondas Inc. (NASDAQ:ONDS) provides autonomous systems, robotics, counter-drone technologies, private wireless networks, and mission-critical defense and security platforms.

2. Legend Biotech Corporation (NASDAQ:LEGN)

Legend Biotech Corporation (NASDAQ:LEGN), with upside potential of 105.7%, ranks among the under-the-radar stocks with massive upside for 2026.

With continued CARVYKTI growth fueling a strong first quarter, Legend Biotech Corporation (NASDAQ:LEGN) is nearing adjusted profitability this year, drawing attention from multiple analysts.

On May 13, 2026, RBC Capital analyst Leonid Timashev raised the firm’s price target on Legend Biotech Corporation (NASDAQ:LEGN) to $64 from $62 and kept an “Outperform” rating following better-than-expected Q1 results. Timashev called it a good quarter for CARVYKTI, citing increasing penetration into earlier treatment lines, expansion into the community setting, and limited competitive pressure. HC Wainwright and Morgan Stanley also reiterated bullish ratings on the stock following the quarter.

Those analyst updates followed Legend Biotech Corporation (NASDAQ:LEGN)’s Q1 2026 results reported on May 12, 2026.

CARVYKTI net trade sales reached approximately $597 million, up 52% year-over-year, with U.S. sales growing 36% and ex-U.S. sales surging more than 200%. Total revenue came in at $305 million, with collaboration revenue from the Janssen partnership rising 61% to $298.4 million. Net loss narrowed to $54.3 million from $101.0 million a year earlier. Adjusted net loss improved to $10.5 million from $27.0 million, with Legend Biotech Corporation (NASDAQ:LEGN)’s management reaffirming guidance for company-wide adjusted profitability in 2026.

CARVYKTI is now approved in 18 global markets across more than 300 treatment sites. Legend Biotech Corporation (NASDAQ:LEGN) reported a 99% manufacturing success rate and a median turnaround time of approximately 29 days. Gross margin on net product sales declined to 41% from 57% the prior quarter, due to one-time expenses tied to manufacturing capacity expansion. CFO Carlos Santos said that without that charge, the company would have been profitable on an adjusted basis.

Cash, cash equivalents, and time deposits stood at approximately $835 million with no long-term debt.

Legend Biotech Corporation (NASDAQ:LEGN) is a commercial-stage biopharmaceutical company that develops innovative therapies. Being an end-to-end cell therapy company, they focus on medication for serious diseases such as hematologic malignancies and solid tumors.

1. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

With an analyst consensus upside of 126.9%, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks among the under-the-radar stocks with massive upside for 2026.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) drew fresh analyst attention after multiple updates tied to the rollout of PALSONIFY and the company’s broader endocrine pipeline.

On May 11, 2026, Oppenheimer lowered its price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $84 from $87 while maintaining an “Outperform” rating following quarterly results.

The firm pointed to continued enrollment in the Phase 3 carcinoid syndrome study and ongoing pivotal and Phase 2 trials for atumelnant in adult and pediatric congenital adrenal hyperplasia (CAH), with a Phase 2/3 study in ACTH-dependent Cushing’s syndrome expected to begin soon. Oppenheimer also said it is watching for initial clinical data from CRN09682 in neuroendocrine tumors later this year.

That followed Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)’s May 7, 2026, first-quarter report, which showed revenue rising to $10.7 million from $0.4 million a year earlier, including $10.3 million in net product revenue from PALSONIFY. The company received 232 enrollment forms during the quarter, while 263 unique healthcare providers prescribed the treatment within its first two quarters on the market. About 70% of patients on PALSONIFY at quarter-end were receiving reimbursed therapy.

Meanwhile, Citizens lowered its price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $95 from $97 on May 8, 2026, while keeping an “Outperform” rating, citing PALSONIFY’s expanding prescriber adoption and improving reimbursement trends.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ended the quarter with $1.3 billion in cash, cash equivalents, and investment securities and maintained its 2026 GAAP operating expense guidance of $600 million to $650 million.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is engaged in developing and marketing innovative treatments for rare endocrine diseases and endocrine-related tumors. The company offers a range of therapies that are currently in different stages of clinical trials. These include Paltusotine, Atumelnant, CRN09682, oral GLP-1, and GIP nonpeptide.

READ NEXT: 9 Best Cloud Stocks to Buy as Azure Growth Hits 40% and 10 Best Nuclear Energy Stocks to Buy as SMRs Go Mainstream.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.